Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study supports a probable causal association between IGF-1 and breast cancer

Key clinical point: Higher insulin-like growth factor-1 (IGF-1) concentrations are associated with an increased risk of breast cancer.

Major finding: In multivariable-adjusted models, higher IGF-1 levels were associated with a greater risk of breast cancer (hazard ratio [HR] per 5 nmol/L increment of IGF-1, 1.11; 95% confidence interval, 1.07-1.16). In Mendelian randomization (MR) analyses, the risk of breast cancer increased by 5% for each 5 nmol/L increase in genetically predicted IGF-1 levels (P = .02).

Study details: The data come from an observational study (206,263 women in the UK Biobank) and MR analyses (genome-wide data from 122,977 patients and 105,974 control participants).

Disclosures: No study sponsor was identified. The authors declared no conflict of interest.

Citation:

Murphy N et al. Ann Oncol. 2020 Mar 10. doi: 10.1016/j.annonc.2020.01.066.